Trial Report Metabolomic and immune alterations in long COVID patients with chronic fatigue syndrome, 2024, Saito

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1341843/abstract

Metabolomic and immune alterations in long COVID patients with chronic fatigue syndrome

ORIGINAL RESEARCH article
Front. Immunol.
Sec. Viral Immunology
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1341843
This article is part of the Research Topic
Cross-Reactive Immunity and COVID-19

Suguru Saito1 Shima Shahbaz1 Xian Luo1 Mohammed Osman1 Desiree Redmond1 Jan Willem Cohen Tervaert1 Liang Li1 Shokrollah Elahi1*

• 1University of Alberta, Canada

The final, formatted version of the article will be published soon.


A group of SARS-CoV-2 infected individuals present lingering symptoms, defined as long COVID (LC), that may last months or years post the onset of acute disease.

A portion of LC patients have symptoms similar to myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS), which results in a substantial reduction in their quality of life.

A better understanding of the pathophysiology of LC, in particular, ME/CFS is urgently needed.

We identified and studied metabolites in LC individuals mainly exhibiting ME/CFS compared to age-sex-matched recovered individuals (R) without LC, acute COVID-19 patients (A), and to SARS-CoV-2 unexposed healthy individuals (HC).

Through these analyses, we identified alterations in several metabolomic pathways in LC vs other groups.

Plasma metabolomics analysis showed that LC differed from the R and HC groups.

Of note, the R group also exhibited a different metabolomic profile than HC. Moreover, we observed a significant elevation in the plasma proinflammatory biomarkers (e.g. IL-1a, IL-6, TNF-a, Flt-1, and sCD14) but the reduction in ATP in LC patients.

Our results demonstrate that LC patients exhibit persistent metabolomic abnormalities 12 months after the acute COVID-19 disease.

Of note, such metabolomic alterations can be observed in the R group 12 months after the acute disease.

Hence, the metabolomic recovery period for infected individuals with SARS-CoV-2 might be long-lasting.

In particular, we found a significant reduction in sarcosine and serine concentrations in LC patients, which was inversely correlated with depression, anxiety, and cognitive dysfunction scores.

Therefore, our study findings provide a comprehensive metabolomic knowledge base for a better understanding of the pathophysiology of LC and suggests sarcosine and serine supplementations might have potential therapeutic implications in LC patients.

Finally, our study reveals that LC disproportionally affects females more than males, as evidenced by nearly 70% of our LC patients being female.



Keywords: Sarcosine, Serine, soluble CD14, Depression, Cognitive Performance

Received: 21 Nov 2023; Accepted: 04 Jan 2024.

 

Now published.

 

Those markers look really familiar from somewhere.

 

Press release for this Canadian study [Metabolomic and immune alterations in #longCOVID patients with #ChronicFatigueSyndrome]:
https://www.ualberta.ca/folio/2024/...ly-identical-to-chronic-fatigue-syndrome.html

“We do not actually believe that #longCOVID is a separate new disease,” explains rheumatologist and clinical immunologist Jan Willem Cohen Tervaert, professor of medicine, who is an expert in fatigue associated with rheumatic illnesses. (contd)"

(Contd) “Some symptoms — such as the loss of taste and chest pain — are very specific for #COVID, but we see a common pathway with ME/CFS, which leads to the same fatigue, brain fog, post-exertional malaise, widespread pain and non-refreshing sleep,” he says. #MEcfs #CFS #PwME